LONDON – A hitch at Algeta ASA's new facility for manufacturing commercial supplies of Alpharadin has pushed back the filing date for the alpha radiation treatment for bone metastases from midyear to the end of 2012. Read More

By using a forward genetics approach, two separate teams of researchers have identified related genes as potential oncogenes and mediators of receptor tyrosine kinase inhibitors. Their findings were published back-to-back in the Aug. 13, 2012, online issue of the Journal of Clinical Investigation. Read More

LONDON – The European Medicines Agency (EMA) is embroiled in a fresh row about its lax stance on ensuring there are no conflicts of interest when senior staff resign and take up outside posts, after its top legal expert joined the life sciences practice of a U.S. law firm the week after leaving the agency. Read More

Clinical testing of Affitech A/S's lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors. Read More

Regulus Therapeutics Inc., of La Jolla, Calif., inked another two deals related to its microRNA technology. Its agreement with London-based AstraZeneca plc calls for a $28 million up-front cash and equity payment, plus milestones, for development of three microRNA targets. Read More

• Nordic Bioscience A/S, of Copenhagen, Denmark, and Unigene Laboratories Inc., of Boonton, N.J., disclosed the preliminary selection of a lead compound for Type II diabetes under the firms' joint development vehicle (JDV). Read More